Mediterranean Diet Modulation of Neuroinflammation-Related Genes in Elderly Adults at High Cardiovascular Risk.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
18 Sep 2024
Historique:
received: 04 09 2024
revised: 12 09 2024
accepted: 13 09 2024
medline: 29 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Individuals with dementia and neurodegenerative diseases (NDDs) often suffer from cardiovascular diseases (CVDs). Neuroinflammation driven by conditions involved in CVDs is linked to disruptions in the central nervous system triggering immune reactions, perpetuating an "inflammatory-like" environment. The Mediterranean diet (MedDiet), known for its anti-inflammatory and antioxidant properties, has been proposed as a key factor to attenuate these risks. Blood nuclear cell samples were collected from 134 participants of the PREDIMED trial, which randomized participants to three diets: one supplemented with extra-virgin olive oil (MedDiet-EVOO), another with nuts (MedDiet-Nuts), and a low-fat control diet. These samples were analyzed at baseline and 12-month follow-up to assess the impact of these dietary interventions on gene expression markers. We first selected target genes by analyzing intersections between NDD and CVD associations. Significant gene expression changes from baseline to 12 months were observed in the participants allocated to the MedDiet-EVOO, particularly in CDKN2A, IFNG, NLRP3, PIK3CB, and TGFB2. Additionally, TGFB2 expression changed over time in the MedDiet-Nuts group. Comparative analyses showed significant differences in TGFB2 between MedDiet-EVOO and control, and in NAMPT between MedDiet-Nuts and control. Longitudinal models adjusted for different covariates also revealed significant effects for TGFB2 and NAMPT. In conclusion, our results suggest that one year of traditional MedDiet, especially MedDiet-EVOO, modulates gene expression associated with CVD risk and NDDs in older adults at high CV risk.

Identifiants

pubmed: 39339745
pii: nu16183147
doi: 10.3390/nu16183147
pii:
doi:

Substances chimiques

Olive Oil 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI18/00020
Organisme : Instituto de Salud Carlos III
ID : PI19/00017
Organisme : Instituto de Salud Carlos III
ID : PI16/00533
Organisme : Instituto de Salud Carlos III
ID : PI13/00233
Organisme : Instituto de Salud Carlos III
ID : PI20/00012
Organisme : Instituto de Salud Carlos III
ID : CP21/00097
Organisme : Instituto de Salud Carlos III
ID : PI17/00214
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : 2021 SGR 00144
Organisme : Instituto de Salud Carlos III
ID : CM20/00085

Auteurs

Javier Hernando-Redondo (J)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute, 08024 Barcelona, Spain.
Ph.D. Program in Food Science and Nutrition, University of Barcelona, 08028 Barcelona, Spain.

Mireia Malcampo (M)

Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute, 08024 Barcelona, Spain.

Karla Alejandra Pérez-Vega (KA)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute, 08024 Barcelona, Spain.

Indira Paz-Graniel (I)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Departament de Bioquímica i Biotecnologia, Alimentació, Nutrició, Desenvolupament i Salut Mental ANUT-DSM, Universitat Rovira i Virgili, 43201 Reus, Spain.

Miguel Ángel Martínez-González (MÁ)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Department of Preventive Medicine and Public Health, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad de Navarra, 31009 Pamplona, Spain.

Dolores Corella (D)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Departament of Preventive Medicine, University of Valencia, 46010 Valencia, Spain.

Ramón Estruch (R)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Departament of Internal Medicine, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, 46010 Barcelona, Spain.

Jordi Salas-Salvadó (J)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Departament de Bioquímica i Biotecnologia, Alimentació, Nutrició, Desenvolupament i Salut Mental ANUT-DSM, Universitat Rovira i Virgili, 43201 Reus, Spain.

Xavier Pintó (X)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Lipids and Vascular Risk Unit, Internal Medicine, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitario de Bellvitge, University of Barcelona, 08028 Barcelona, Spain.

Fernando Arós (F)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Cardiology Department, Organización Sanitaria Integrada Araba (OSI ARABA), University Hospital of Araba, 01009 Gasteiz, Spain.
University of País Vasco/Euskal Herria Unibersitatea (UPV/EHU), 01006 Vitoria-Gasteiz, Spain.

Inmaculada Bautista-Castaño (I)

Institute for Biomedical Research, University of Las Palmas de Gran Canaria, 35001 Las Palmas de Gran Canaria, Spain.

Dora Romaguera (D)

Research Group in Nutritional Epidemiology and Cardiovascular Pathophysiology, Instituto de Investigación Sanitaria Illes Balears (IdISBa), 07120 Palma de Mallorca, Spain.

José Lapetra (J)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Department of Family Medicine, Research Unity, Distrito Sanitario Atención Primaria Sevilla, 41013 Seville, Spain.

Emilio Ros (E)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, 46010 Barcelona, Spain.

Raquel Cueto-Galán (R)

Preventive Medicine and Public Health Department, School of Medicine, University of Malaga, Spain, Biomedical Research Institute of Malaga (IBIMA), 29071 Malaga, Spain.

Montserrat Fitó (M)

CIBER de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute, 08024 Barcelona, Spain.

Olga Castañer (O)

Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute, 08024 Barcelona, Spain.
CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH